✦ LIBER ✦

EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE): A cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome

✍ Scribed by William B. White; George L. Bakris; Richard M. Bergenstal; Christopher P. Cannon; William C. Cushman; Penny Fleck; Simon Heller; Cyrus Mehta; Steven E. Nissen; Alfonso Perez; Craig Wilson; Faiez Zannad

Book ID: 116192592
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 225 KB
Volume: 162
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2011.08.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of the dipeptidyl pe

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

✍ R. E. Pratley; M. S. Kipnes; P. R. Fleck; C. Wilson; Q. Mekki; Alogliptin Study 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

Efficacy and safety of the dipeptidyl pe

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

✍ I. Raz; M. Hanefeld; L. Xu; C. Caria; D. Williams-Herman; H. Khatami; Sitaglipti 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 160 KB

Retrospective analysis of cardiovascular

Retrospective analysis of cardiovascular outcomes in patients with type 2 diabetes mellitus after the first acute myocardial infarction

✍ B. Możejko-Pastewka; J. Tatoń; J. Haczyński; K. Strojek; A.S. Ametov; Z. Milicev 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 82 KB

Pharmacokinetic, pharmacodynamic, and to

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

✍ Paul Covington; Ronald Christopher; Michael Davenport; Penny Fleck; Qais A. Mekk 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 253 KB

Efficacy and safety of adding the dipept

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

✍ M. A. Nauck; G. C. Ellis; P. R. Fleck; C. A. Wilson; Q. Mekki; for the Aloglipti 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB

Treatment of acute coronary syndromes in

Treatment of acute coronary syndromes in patients with type 2 diabetes mellitus with β-adrenoblockers and angiotensin-converting enzyme inhibitors: Cardiohemodynamic effects and impact for prognosis

✍ L. A. Ivanova; S. G. Kanorskii; O. N. Rostovtseva; Basit Halil Sufian; P. A. Gal 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 324 KB